




CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Research Funding Update and Proposal ICOC meeting Agenda Item 6B1

Patricia Olson, Ph.D.
Executive Director, Scientific Activities
December 11, 2013

Current Funding Allocation: Detail



Category	Awarded	Concept Approved	Future: Allocated Scenario I	Future: Unallocated	Total:	% Total	Future: Alloc & Unalloc
Facilities/Core Resources	372.3	70.0	-	-	442	16.1%	-
Training / Career Dev.	362.6	23.0	-	24.8	410	15.0%	24.8
Basic Research	288.1	80.0	100.0	(7.4)	461	16.8%	92.6
Translational Research	284.0	40.0	95.0	43.6	463	16.9%	138.6
Development	484.1	107.5	266.0	102.9	961	35.0%	368.9
Multiple	-	-	-	4.6	5	0.2%	4.6
Total	\$ 1,791.1	\$ 320.5	\$ 461.0	\$ 168.4	\$ 2,741.0	100%	\$ 629.4

Points to Consider

- Of ~\$1.8 B awarded, \$550 MM to be disbursed*
- \$950 MM remains to be awarded (\$321 MM concept approved, \$629 MM future (allocated and unallocated))

* Assumes funding for Duane Roth Disease Team III Therapy Development Awards approved as recommended.

Concept Approved

Category	Approved Concepts	\$ MM	Category, \$ MM
Facilities, Core Resources	Alpha Stem Cell Clinics	70.0	70.0
Training, Career Development	Research Leaders	23.0	23.0
Basic Research	Basic Biology V	40.0	80.0
	Stem Cell Genomics	40.0	
Translational Research	Tools and Technologies III	35.0	35.0
Development	Strategic Partnership III	80.0	80.0
Multiple*	External Innovation	15.0	32.5
	Bridging	11.5	
	Extraordinary Supplement	6.0	
Total			320.5

Based on data to date, ~ \$23 - 48 MM (7-15%) of concept approved funding will not be awarded/allocated

* The External Innovation and Extraordinary Supplement Awards can fund Basic, Translational or Development research; Bridging can fund Translational or Development research.

Future Funding: Strategic Plan



Category	Scenario 1			Scenario 2		
	Future Funding	\$ MM	Category \$, MM	Future Funding	\$ MM	Category \$, MM
Facilities, Core Resources	None in scenario 1 <i>Unallocated</i>	- -	-	Shared labs, 2nd extension extension -> 9yr <i>Unallocated</i>	25.0 -	25.0
Training, Career Development	None in scenario 1 <i>Unallocated</i>	- 24.8	24.8	Training II, 2nd extension (reduced funding) Bridges, 2nd extension -> 9yr <i>Unallocated</i>	30.0 30.0 24.8	84.8
Basic Research	Basic Biology VI-VIII <i>Unallocated</i>	100.0 (7.4)	92.6	Basic Biology VI -VII <i>Unallocated</i>	70.0 (7.4)	62.6
Translational Research	Early Translation V Translation award, e.g. TnT4 <i>Unallocated</i>	65.0 30.0 43.6	138.6	Early Translation V Translation award, e.g. TnT4 <i>Unallocated</i>	60.0 - 43.6	103.6
Development	Disease Teams IV-VI Strategic Partnership IV-VI <i>Unallocated*</i>	160.0 100.0 102.9	362.9	Disease Teams IV-VI Strategic Partnership IV-VI <i>Unallocated*</i>	140.0 100.0 102.9	342.9
Multiple	Bridging Fund II <i>Unallocated</i>	6.0 4.6	10.6	Bridging Fund II <i>Unallocated</i>	6.0 4.6	10.6
Total			629.4			629.4

* Future Funding, Development Unallocated, assumes Duane Roth Disease Team III Therapy Development Awards are funded as recommended.

New Scenario for Future Funding: Assumptions

- Implement Management/SAB recommendations
- Compatible with approved strategy
- Clinical Proof-of-Concept (POC) the priority
 - Funding of 6-8 prioritized development programs to clinical POC
 - Most of CIRM's current Development portfolio is funded for the next 3-4 years, including projects that could result in clinical POC in that time frame
- Provide funding opportunities for moving existing meritorious Early Translation towards/into/through development
- Provide funding opportunities for moving existing/new development programs further through development

Future Scenario: Current and Proposed



Category	Future Funding: Current* \$ MM	Category \$, MM	Future Funding: Proposed Scenario	\$ MM	Category \$, MM
Facilities, Core Resources	None in scenario 1 <i>Unallocated</i>	- -	Haplotype Bank	10.0	10.0
Training, Career Development	None in scenario 1 <i>Unallocated</i>	- 24.8	Training II, 2nd 3 yr extension -> 9 yr Bridges, 2nd 3 yr extension -> 9 yr Creativity, 1st extension -> 6 yr	45.0 26.6 1.7	73.3
Basic Research	Basic Biology VI-VIII <i>Unallocated</i>	100.0 (7.4)	Basic Biology (3 additional rounds) <i>Unallocated</i>	100.0 (7.4)	92.6
Translational Research	Early Translation V Translation award, e.g. TnT4 <i>Unallocated</i>	65.0 30.0 43.6	ET Transition awards (DCF to DC/pre-pre IND, 2 rounds)	40.0	40.0
Development	Disease Teams IV-VI Strategic Partnership IV-VI <i>Unallocated</i>	160.0 100.0 102.9	• Follow-on funding for Priority projects • Disease Teams/Strategic Partnership (moving ET and other Development projects forward)	200.0 261.5	461.5
Multiple	Bridging Fund II <i>Unallocated</i>	6.0 4.6	Eliminate to help fund proposed new programs	-	-
Total				Total	677.4

Difference between currently available 'Future Funds' and new Future funding scenario is \$48 MM

- Current here assumes Scenario 1. Future Funding Current, Development 'Unallocated', assumes Duane Roth Disease Team III Therapy Development Awards are approved as recommended.

Funding the Proposed Future Scenario: Options for additional ~\$48 MM

Watchful Waiting (recommended)

- Potential savings from current 'Concept Approved' but not yet awarded RFAs.
 - Based on previous data, 7-10% of concept approved funds (\$ 23 – 32 MM from current concept approved of \$321 MM) will not be awarded and/or will be reduced during pre-funding administrative review
- Not all awards are accepted
 - Based on previous data, 3.7% of concept approved funds (\$11.7 million) though awarded will not be accepted.
- Funding decisions on ~\$ 250 MM (out of \$321 MM) of concept approved programs will be made by July next year

Eliminate/reduce some programs in proposed funding plan
(not recommended)

Summary

- Funding Proposal
 - Implements SAB and management recommendations:
 - Facilitates success of our clinical development program includes training, keeps robust basic research program, moves translational research forward
 - Builds on our strategy and keeps focus on key strategic objectives
 - Is feasible with existing funding